Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2020

View Archived Issues

Activity against AML seen in vitro and in vivo with LSD1 inhibitor CPI-482

Phase II results reported for AXL inhibitor bemcentinib in patients failing hypomethylating agents

Sulanda approved in China for non-pancreatic NETs

Saroglitazar magnesium approved in India for NAFLD

Altimmune initiates phase II trial of HepTcell for chronic hepatitis B

Codiak reports initial phase I data on exoIL-12 for CTCL

Arcturus selects ARCT-032 as development candidate for cystic fibrosis

FDA clears LyGenesis' IND for phase IIa study of cell therapy for end-stage liver disease

Ascendis files IND for TransCon TLR7/8 agonist

Lanzhou University synthesizes siRNAs targeting OLFML2A

New phase I/II study explores use of TY-101 for solid tumors and lymphomas

New AXL/Mer/c-Met/VEGFR-2 inhibitors discovered at Exelixis

Mirati Therapeutics describes new polycomb protein EED inhibitors

Orexin receptor antagonists patented by Hager Biosciences

University of California, Oakland presents inhibitors of activities caused by MECP2 gene mutations

Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor

UBA1 gene mutations linked to novel adult-onset rheumatic disease

ImmunoPrecise Antibodies joins consortium to develop SARS-CoV-2-specific therapeutic nanomedicine

Atlas maps cleaned-up tumor microbiomes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...